Download Library

 
 
 
Download Library
Document Type
Articles of Association dated April 4, 2017
pdf
330.4 KB
Election Results of the Annual General Meeting 2017
PDF
91.4 KB
Scientific Committee Charter
PDF
155.3 KB
AGM 2017 Presentation
PDF
1.4 MB
Genmab 2016 Annual Report
pdf
8.7 MB
Full Year 2016 Results Podcast
MP3
28.2 MB
Full Year 2016 Results Presentation
PDF
488.8 KB
CSR Report 2016
PDF
274.2 KB
Corporate Governance Report 2016 - English
PDF
332.4 KB
Investor Fact Sheet
PDF
1.6 MB
35th Annual J.P. Morgan Healthcare Conference, San Francisco, CA, US - January 2017
PDF
1.2 MB
Use of Montelukast to Reduce Infusion Reactions in an Early Access Program (EAP) of Daratumumab in United States Patients With Relapsed or Refractory Multiple Myeloma - ASH Poster - December 2016 (Chari)
PDF
545.4 KB
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of CASTOR - ASH Poster - December 2016 (Chanan-Khan)
PDF
470.6 KB
Cost-effective Analysis of Ofatumumab for Relapsed CLL - ASH poster - December 2016 (Tremblay)
PDF
279.5 KB
Genmab's ASH 2016 Data Review Meeting, San Diego, CA - December 2016
PDF
3.3 MB
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory MM Pts Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action - ASH poster - December 2016 (Adams)
PDF
4.9 MB
DRd Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX) - ASH poster - December 2016 (Chiu)
PDF
888.9 KB
Efficacy of DVd Versus Vd in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor - ASH presentation - December 2016 (Mateos)
PDF
1.3 MB
Efficacy of DRd Versus Rd in Relapsed or Refractory MM Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux - ASH presentation - December 2016 (Usmani)
PDF
1.4 MB
Phase 1b Study to Assess Subcutaneous Daratumumab in pts with Relapsed or Refractory MM (PAVO) - ASH presentation - December 2016 (Usmani)
PDF
981.3 KB
Adjusted Comparisons Suggest Daratumumab Is Associated with Prolonged Survival Compared with Standard of Care in pts with Heavily Pre-Treated & Highly Refractory MM - ASH poster - December 2016 (Kumar)
PDF
530.3 KB
Evaluation of MRD in Relapsed/Refractory MM Patients Treated with Daratumumab in Combination with Rd or Vd - ASH presentation - December 2016 (Avet-Loiseau)
PDF
2.6 MB
Comparative Effectiveness of Daratumumab Versus a Real-World Historical Control in Heavily Pretreated and Highly Refractory MM - ASH poster - December 2016 (Hájek)
PDF
308.5 KB

Page:
1
2
3
4
5
...
16
Next Last

 
 
 

Please be advised that additional documents and media, such as fact sheets and conference call webcasts, are available only in English and can be accessed by clicking on the English tab.

 

Download Library
Document Type
Selskabsvedtægter dateret den. 4. april 2017
pdf
306.9 KB
Resumé 2016
PDF
2.4 MB
Adjusted Comparisons Suggest Daratumumab Is Associated with Prolonged Survival Compared with Standard of Care in pts with Heavily Pre-Treated & Highly Refractory MM - ASH poster - December 2016 (Kumar)
PDF
530.3 KB
Management of transaminase elevations associated with idelalisib - EHA poster regarding ofatumumab submitted by Gilead - June 2016 (Ghia)
PDF
1.5 MB
Præsentation for Nordnet 30. maj 2016
PDF
1.2 MB
Resumé 2015
PDF
2.6 MB
Selskabsvedtægter dateret den 26. marts 2015
PDF
195.3 KB
Resumé 2014
PDF
1.3 MB
Danish Shareholder Association Event Presentation - September 2014
PDF
822.1 KB
Ordinær generalforsamling 2014 præsentation
PDF
2.6 MB
Samfundsansvar (CSR) - Lovpligtig redegørelse for 2013
URL
N/A
2013 årsrapport
pdf
6.0 MB
Redegørelse for virksomhedsledelse 2013
URL
N/A
Genmab offentliggør resultat for de første ni måneder af 2013
pdf
588.3 KB
Genmab offentliggør resultat for første halvår 2013 og opjusterer forventningerne til 2013
pdf
812.1 KB
Genmab offentliggør resultat for første kvartal 2013
pdf
969.7 KB
Ordinær generalforsamling 2013 præsentation
PDF
1.1 MB
Samfundsansvar (CSR) - Lovpligtig redegørelse for 2012
URL
N/A
Redegørelse for virksomhedsledelse 2012
URL
N/A
2012 årsrapport
pdf
5.7 MB
Genmab offentliggør resultat for de første ni måneder af 2012 og opjusterer forventningerne til 2012
pdf
233.3 KB
Genmab offentliggør resultat for første halvår 2012 og opjusterer forventningerne til 2012
pdf
321.8 KB
Genmab offentliggør resultat for første kvartal 2012
pdf
231.7 KB
Overordnede retningslinjer for incitamentsordninger
PDF
79.0 KB
Lovpligtig redegørelse for virksomhedsledelse 2011
PDF
129.3 KB
Page:
1
2
3
4
Next Last